| abstract |
The invention describes non-steroidal gestagens of the general formula (I) in which R and R are the same or different and denote a hydrogen atom, a C 1 -C 6 alkyl group or a halogen atom, and together with the C-atom form a ring having a total of 3-7 members; R4 represents a C1-4 alkyl group or a partially or fully fluorinated C1-4 alkyl group; A denotes an optionally substituted mono-or bicyclic aromatic ring, an ester group —COOR, an alkenyl group —CR = CRR, an alkynyl group —C-CR or a partially or fully fluorinated C1-3 alkyl group; B represents a carbonyl group or a CH group; and Ar represents a ring system selected from the group of general sub-formulas (2-11). New compounds have a very high degree of affinity for the gestagenic receptor. Individually or in combination with estrogen, they can be used in drugs intended for contraception. In addition, they can be used to treat endometriosis. Together with endrogens, new compounds can be used in drugs for the treatment of gynecological disorders, for the treatment of painful conditions in the premenstrual period, and for replacement therapy. Thanks to their androgenic action, they can also be used to control male fertility, in hormone replacement therapy for men and hormone therapy. With equal success, they can be used to treat diseases associated with the action of androgens. |